The clinical trial process is complex, long, and always arduous. But the results of the drug development process can be amazing, new, safe, effective, life-changing, and life-enhancing therapies.
As the FDA stakes its claim as the primary regulator of AI in healthcare, it must navigate the delicate balance between fostering innovation and ensuring safety and responsibility.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
Moving from spreadsheets to automated data collection and processing is far from easy, but it could revolutionize drug development. It’s time for the biopharma industry to embrace end-to-end digitalization.
The next era for mRNA-based therapeutics and vaccines is here, and it’s time to move from an R&D mindset to a focus on long-term success with mRNA and bringing these innovative therapeutics to patients at scale.
Multiple studies have shown no correlation between R&D costs and the launch price of new drugs though that is an argument often used by drugmakers to prevent a cap on pricing. Still, one way to keep costs low, is for organizations to leverage health technology like AI and improve formulary compliance.
Government funding plays a major role in the advancement of drugs, including monoclonal antibodies, which are extremely expensive to produce and can take months to develop.
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
A drug development approach that makes use of hybrid AI can de-risk drug development while simultaneously removing other barriers to success. In other words, it has the power to significantly reduce the drug development timeline, and ultimately, save more lives.
Antisense oligonucleotides (ASOs) have faced their share of challenges, but a combination of research advances and a market ripe for innovation is setting this drug class up for a resurgence. Antisense oligonucleotide (ASO)—a class of drugs that works by targeting RNA to alter gene expression and control aberrant proteins in ways that traditional drugs can’t.
Rich Horgan believes that there's an alternative path to drug development that can lower costs and the time it takes to bring drugs to market. He is trying to apply it to the field of rare and ultra-rare diseases.
Drug developers need policies and technological infrastructure to execute on their goal of being patient-focused. At a minimum, this means a compliant way to engage patients and truly hear their voices; at its most effective, patient engagement also meets patients where they are – whenever and wherever that may be.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
Abcam’s acquisition comes two months after its board announced the exploration of strategic alternatives that could include the sale of the company. Danaher beat out at least 20 companies that were potential buyers of the life sciences tools and antibody development firm.
Biopharma companies are harnessing AI tools for multiple aspects of drug development such as identifying drug development targets, modeling a drug's effect on the body, and more.
Risk-based quality management, or RBQM, is the process by which pharmaceutical organizations monitor and manage quality throughout clinical trials.
Boston Consulting Group hosted a panel during the annual J.P. Morgan Healthcare Conference in which Merck'c chief strategy officer, a healthcare leader from Goldman Sachs, an investment executive and a senior medical devices executive from Medtronic weighed in on trends the life sciences industry can expect to see in 2023.
Many pharma and medical device companies will look inward, with the goal of standardizing and modernizing even highly regulated activities. Here’s a closer look at some important industry trends for 2023.